gene	cnvType	source	drug	drugType	cancerType	level	hmfLevel	evidenceType	significance	hmfResponse
ERBB2	Amplification	oncoKb	Lapatinib + Trastuzumab	ERBB2 inhibitor + ERBB2 mAb inhibitor	Breast Cancer	1	A	Predictive	Responsive	Responsive
ERBB2	Amplification	oncoKb	Pertuzumab + Trastuzumab	ERBB2 mAb inhibitor + ERBB2 mAb inhibitor	Breast Cancer	1	A	Predictive	Responsive	Responsive
BRCA2	Deletion	cgi	Olaparib	PARP inhibitor	Ovary	Pre-clinical	D	Predictive	Responsive	Responsive
ERBB2	Amplification	cgi	Pertuzumab	ERBB2 mAb inhibitor	Billiary tract	Early trials	C	Predictive	Responsive	Responsive
ERBB2	Amplification	cgi	Trastuzumab	ERBB2 mAb inhibitor	Stomach	FDA guidelines	A	Predictive	Responsive	Responsive
